Skip to main content
SpringerLink
Log in

UGT1A1 polymorphism predicts irinotecan toxicity: Evolving proof

  • Published:
AAPS PharmSci Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Innocenti F, Iyer L, Ratain MJ. Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan. Drug Metab Dispos 2001; 29:596–600.

    CAS  PubMed  Google Scholar 

  2. Kehrer DF, Sparreboom A, Verweij J, de Bruijn P, Nierop CA, van de Schraaf J, Ruijgrok EJ, de Jonge MJ. Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. Clin Cancer Res 2001;7:1136–41.

    CAS  PubMed  Google Scholar 

  3. Ostrow JD, Tiribelli C. Variation in UGT 1A1 activity in Gilberts syndrome. J Hepatol 2001; 34:636–94.

    Article  CAS  PubMed  Google Scholar 

  4. Kadakol A, Ghosh SS, Sappal BS, Sharma G, Chowdhury JR, Chowdhury NR. Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype. Hum Mutat 2000; 16:297–306.

    Article  CAS  PubMed  Google Scholar 

  5. Iyer L, Hall D, Das S, Mortell MA, Ramirez J, Kim S, Di Rienzo A, Ratain MJ. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT 1A1 promoter polymorphism. Clin Pharmacol Ther 1999; 65:576–82.

    Article  CAS  PubMed  Google Scholar 

  6. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka, H, Yokoyama A, Saitoh S, Shimokata K, Hasegawa Y. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000; 60:6921–6.

    CAS  PubMed  Google Scholar 

  7. Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT 1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci U S A 1998; 95:8170–4.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Weiler/AECOM, Room 2S-63, 1825 Eastchester Road, 10461, Bronx, NY

    Sridhar Mani

Authors
  1. Sridhar Mani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sridhar Mani.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mani, S. UGT1A1 polymorphism predicts irinotecan toxicity: Evolving proof. AAPS PharmSci 3, Commentary 2 (2001). https://doi.org/10.1208/ps0303_commentary2

Download citation

  • Published:

  • DOI: https://doi.org/10.1208/ps0303_commentary2

Keywords

Search

Navigation